Gain Therapeutics Inc
GANX
NASDAQ
Biotechnology
$2.12
USD
-0.05 (-2.08%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $94.49M
Volume 517.4K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-21.24M
TTM
-1.5%
YoY
Operating Cash Flow
$-19.37M
TTM
-1.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.1 | 2.3 | 1.9 | 2.1 | 2.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 4.4 | 5.1 | 4.8 | 4.5 | 5.4 |
Operating Income | -4.4 | -5.1 | -4.8 | -4.5 | -5.4 |
EBITDA | -4.3 | -5.1 | -4.8 | -4.4 | -5.3 |
Other Income / Expense | -0.1 | -0.6 | -0.0 | -0.1 | -0.2 |
Total Other Income / Expense | -0.1 | -0.6 | 0.1 | -0.0 | -0.1 |
Income Before Income Taxes | -4.4 | -5.7 | -4.7 | -4.5 | -5.4 |
Income Taxes | 0.1 | 0.1 | 0.5 | 0.1 | 0.2 |
Net Income | -4.5 | -5.8 | -5.3 | -4.5 | -5.6 |
Consolidated Net Income / Loss | -4.5 | -5.8 | -5.3 | -4.5 | -5.6 |
Net Income Attributable to Common Shareholders | -4.5 | -5.8 | -5.3 | -4.5 | -5.6 |
Basic EPS | -$0.16 | -$0.19 | -$0.15 | -$0.12 | -$0.13 |
Diluted EPS | -$0.16 | -$0.19 | -$0.15 | -$0.12 | -$0.13 |
Basic Shares Outstanding | 28.7M | 30.3M | 35.0M | 37.8M | 42.2M |
Diluted Shares Outstanding | 28.7M | 30.3M | 35.0M | 37.8M | 42.2M |